#China #Wuxi #radiopharmaceuticals #NORROY BIOSCIENCE #EANM' 26

NORROY BIOSCIENCE Showcases Innovative Groundbreaking Research at EANM' 26

NORROY BIOSCIENCE, a leader in the biotechnology sector, made significant strides at the recent 39th Annual Congress of the European Association of Nuclear Medicine (EANM' 26). The event, held from October 17 to 21 in Vienna, Austria, placed a spotlight on the company's commitment to advancing the field of radiopharmaceuticals through an impressive display of research and innovation.

During this highly anticipated congress, NORROY featured its cutting-edge capabilities through eight Top Rated Oral Presentations (TROP) and three e-posters. These presentations not only introduced breakthrough therapies but also showcased the company’s proprietary pipelines that stand at the forefront of radiopharmaceutical technology.

Highlighting Breakthrough Innovations

Among the pivotal presentations, NORROY introduced its first innovative radiopharmaceutical originating from China, which has successfully attained both Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD). This groundbreaking development indicates NORROY’s leadership in the global radiopharmaceutical space. Furthermore, the company presented the first terbium-161-based radiopharmaceutical targeting prostate cancer—a promising advancement in the therapeutic landscape.

The presentations highlighted various radionuclides such as 18F, 68Ga, and 177Lu, which are integral to diagnostics and targeted therapy. The research further explored future alternatives with 161Tb, forecasting next-generation treatment options for patients. Additionally, therapeutic targets such as ACP3 and GPC3 were explored with indications ranging from prostate cancer to complex cases like renal cell carcinoma and neuroendocrine tumors.

Collaborations at KUNLUN SALON

In a strategic move, NORROY hosted the KUNLUN SALON, a themed ecosystem forum that encouraged engagement and collaboration with several international partners including Esente Healthcare. Chaired by Dr. Thomas Tulip, the forum reached preliminary agreements aimed at developing radiopharmaceutical automation equipment. This initiative marks a significant expansion in NORROY’s global network of industry partners, further solidifying its position as a pioneering force in biopharmaceutical innovation.

Insightful Presentations from Experts

Dr. Oliver Sartor, an accomplished figure in prostate cancer research, participated in the congress, delivering a crucial oral presentation on “Initial Safety and Efficacy of 177Lu-NYM032 in Progressive mCRPC A Phase I–II Study.” His contribution, alongside participation in the KUNLUN SALON, underscored the depth of expertise behind NORROY’s innovations.

NORROY’s efforts included delving into molecular imaging studies utilizing carbonic anhydrase IX (CAIX) for detecting clear cell renal cell carcinoma (ccRCC). Notable research examined 68Ga-NYM096 for accuracy in lesion detection and real-time imaging capabilities.

Frontiers in Prostate Cancer Research

The spotlight on prostate cancer continued as NORROY introduced radiopharmaceutical candidates focused on the PSMA target. The 161Tb-labeled NYM032 was showcased in initial human studies, marking a significant milestone in clinical trials. Furthermore, findings on the candidate 68Ga/177Lu-NY129 offered promising prospects for molecular imaging applications in prostate cancer treatment.

Innovation Meets Technology

NORROY also showcased its integrated strategy combining radiopharmaceuticals with advanced production equipment at their booth. The focus on AI-enabled drug discovery and automated solutions highlighted NORROY’s commitment to improving efficiency in radiopharmaceutical manufacturing.

The event unveiled a suite of essential production technologies including:

• - Mortenon M1 multifunctional synthesis module
• - Mortenon P1 automated production line
• - Mortenon S3/S4 radionuclide dispensing modules
• - Mortenon D2 radiopharmaceutical transport containers

These technological advancements demonstrate NORROY’s capacity to streamline production while ensuring high-quality radiopharmaceuticals.

The Future of Radiopharmaceuticals

As NORROY BIOSCIENCE looks forward, it remains dedicated to enhancing its research capabilities through continued investment in radiopharmaceutical innovation and automation technologies. This effort is crucial for advancing their pipelines while forging collaborations that support the growth of nuclear medicine.

Founded in July 2021, NORROY has undertaken significant steps, achieving six IND clearances from the FDA and six IND approvals from the National Medical Products Administration (NMPA). The company is keen on maintaining its momentum, actively engaging with global regulatory agencies to further advance its clinical programs through internationally recognized trials. For those eager to learn more about NORROY and their contributions to biopharmaceuticals, further details are available at norroybiopharm.com.